Literature DB >> 24442094

Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat.

Jennifer Li1, Keita Ishiwari2, Michael W Conway1, Jennifer Francois1, John Huxter1, John P Lowry3, Adam J Schwarz4, Mark Tricklebank1, Gary Gilmour1.   

Abstract

Typical and atypical antipsychotics have been shown to alleviate N-methyl-D-aspartate (NMDA) receptor antagonist-induced BOLD signals in healthy humans and animals to differing degrees; factors that might relate to their different molecular mechanisms and clinical profiles. Recent studies have also extended these investigations to the analysis of resting state functional connectivity measures of BOLD signals in different brain regions. Using constant potential amperometry, we examined the effects of the NMDA receptor antagonist S-(+)-ketamine on tissue oxygen levels in medial prefrontal cortex (mPFC) and medial ventral striatum (mVS), and temporal coherence of low-frequency oxygen fluctuations between these regions in freely moving rats. Furthermore, we assessed the extent to which the atypical antipsychotic clozapine and the typical antipsychotic haloperidol could modulate the effects of S-(+)-ketamine on these measures. Acute S-(+)-ketamine (5-25 mg/kg) produced dose-dependent increases in both tissue O2 levels and coherence. Although effects of clozapine and haloperidol alone were relatively minor, their effects on ketamine-induced signals were markedly more distinct. Clozapine dose-dependently attenuated the absolute S-(+)-ketamine (25 mg/kg) O2 signal in both regions, and also attenuated ketamine-induced increases in regional coherence. Haloperidol had no effect on the absolute ketamine O2 signal yet potentiated increases in regional coherence. The dissociable effects of haloperidol and clozapine on ketamine-induced hyperoxygenation and mPFC-mVS coherence elucidate potentially important mechanistic differences between these classes of pharmacology. This study demonstrates for the first time that in vivo amperometry can measure both regional brain tissue O2 levels and inter-regional coherence, advancing BOLD-like measurements of functional connectivity into awake, unconstrained animals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442094      PMCID: PMC4023136          DOI: 10.1038/npp.2014.10

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  42 in total

1.  Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice.

Authors:  S Miyamoto; J N Leipzig; J A Lieberman; G E Duncan
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

2.  Characterization of carbon paste electrodes in vitro for simultaneous amperometric measurement of changes in oxygen and ascorbic acid concentrations in vivo.

Authors:  J P Lowry; M G Boutelle; R D O'Neill; M Fillenz
Journal:  Analyst       Date:  1996-06       Impact factor: 4.616

Review 3.  [From the racemate to the eutomer: (S)-ketamine. Renaissance of a substance?].

Authors:  H A Adams; C Werner
Journal:  Anaesthesist       Date:  1997-12       Impact factor: 1.041

4.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

5.  NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

Authors:  A K Malhotra; D A Pinals; H Weingartner; K Sirocco; C D Missar; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1996-05       Impact factor: 7.853

6.  Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans.

Authors:  William M Howe; Anne S Berry; Jennifer Francois; Gary Gilmour; Joshua M Carp; Mark Tricklebank; Cindy Lustig; Martin Sarter
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

7.  Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.

Authors:  O M Doyle; S De Simoni; A J Schwarz; C Brittain; O G O'Daly; S C R Williams; M A Mehta
Journal:  J Pharmacol Exp Ther       Date:  2013-01-31       Impact factor: 4.030

8.  Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers.

Authors:  S De Simoni; A J Schwarz; O G O'Daly; A F Marquand; C Brittain; C Gonzales; S Stephenson; S C R Williams; M A Mehta
Journal:  Neuroimage       Date:  2012-09-23       Impact factor: 6.556

9.  Hemodynamic responses in amygdala and hippocampus distinguish between aversive and neutral cues during Pavlovian fear conditioning in behaving rats.

Authors:  Stephen B McHugh; Andre Marques-Smith; Jennifer Li; J N P Rawlins; John Lowry; Michael Conway; Gary Gilmour; Mark Tricklebank; David M Bannerman
Journal:  Eur J Neurosci       Date:  2012-11-22       Impact factor: 3.386

10.  Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.

Authors:  N R Driesen; G McCarthy; Z Bhagwagar; M Bloch; V Calhoun; D C D'Souza; R Gueorguieva; G He; R Ramachandran; R F Suckow; A Anticevic; P T Morgan; J H Krystal
Journal:  Mol Psychiatry       Date:  2013-01-22       Impact factor: 15.992

View more
  8 in total

Review 1.  Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry.

Authors:  Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven
Journal:  Hum Brain Mapp       Date:  2017-02-01       Impact factor: 5.038

Review 2.  Unraveling the miswired connectome: a developmental perspective.

Authors:  Adriana Di Martino; Damien A Fair; Clare Kelly; Theodore D Satterthwaite; F Xavier Castellanos; Moriah E Thomason; R Cameron Craddock; Beatriz Luna; Bennett L Leventhal; Xi-Nian Zuo; Michael P Milham
Journal:  Neuron       Date:  2014-09-17       Impact factor: 17.173

3.  Dissociation of mGlu2/3 agonist effects on ketamine-induced regional and event-related oxygen signals.

Authors:  Jennifer Francois; Francois Gastambide; Michael Warwick Conway; Mark Tricklebank; Gary Gilmour
Journal:  Psychopharmacology (Berl)       Date:  2015-05-06       Impact factor: 4.530

4.  Using Intermediate Cognitive Endpoints to Facilitate Translational Research in Psychosis.

Authors:  Gary Gilmour; Francois Gastambide; Hugh M Marston; Mark E Walton
Journal:  Curr Opin Behav Sci       Date:  2015-08-01

5.  The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain.

Authors:  Caterina Montani; Carola Canella; Adam J Schwarz; Jennifer Li; Gary Gilmour; Alberto Galbusera; Keith Wafford; Daniel Gutierrez-Barragan; Andrew McCarthy; David Shaw; Karen Knitowski; David McKinzie; Alessandro Gozzi; Christian Felder
Journal:  Neuropsychopharmacology       Date:  2020-12-20       Impact factor: 7.853

6.  Resting state brain networks in the prairie vole.

Authors:  Juan J Ortiz; Wendy Portillo; Raul G Paredes; Larry J Young; Sarael Alcauter
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

7.  Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation.

Authors:  Marion Rame; Dorian Caudal; Esther Schenker; Per Svenningsson; Michael Spedding; Thérèse M Jay; Bill P Godsil
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

8.  Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.

Authors:  Joshua T Kantrowitz; Jack Grinband; Donald C Goff; Adrienne C Lahti; Stephen R Marder; Lawrence S Kegeles; Ragy R Girgis; Tarek Sobeih; Melanie M Wall; Tse-Hwei Choo; Michael F Green; Yvonne S Yang; Junghee Lee; Guillermo Horga; John H Krystal; William Z Potter; Daniel C Javitt; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2020-05-13       Impact factor: 7.853

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.